Healthcare [ 7/13 ] | Diagnostics & Research [ 58/163 ]
NASDAQ | Common Stock
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.
The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs.
The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA.
It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients.
The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016.
Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 3, 24 | -0.01 Increased by +95.45% | -0.32 Increased by +96.88% |
| Feb 28, 24 | 0.28 Increased by +158.33% | -0.29 Increased by +196.55% |
| Nov 3, 23 | -0.39 Decreased by -221.88% | -0.33 Decreased by -18.18% |
| Aug 4, 23 | -0.08 Decreased by -110.26% | -0.33 Increased by +75.76% |
| May 5, 23 | -0.22 Decreased by -104.33% | -0.43 Increased by +48.84% |
| Feb 28, 23 | -0.48 Decreased by -114.37% | -0.56 Increased by +14.29% |
| Nov 7, 22 | 0.32 Decreased by -91.90% | 0.05 Increased by +540.00% |
| Aug 4, 22 | 0.78 Decreased by -68.42% | 0.73 Increased by +6.85% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 64.48 M Decreased by -2.54% | -13.46 M Increased by +15.06% | Decreased by -20.88% Increased by +12.84% |
| Dec 31, 23 | 70.50 M Increased by +4.14% | -128.15 M Decreased by -432.27% | Decreased by -181.76% Decreased by -411.12% |
| Sep 30, 23 | 84.69 M Decreased by -19.85% | -13.11 M Decreased by -1.08 K% | Decreased by -15.48% Decreased by -1.32 K% |
| Jun 30, 23 | 67.85 M Decreased by -45.87% | -11.23 M Decreased by -197.33% | Decreased by -16.55% Decreased by -279.79% |
| Mar 31, 23 | 66.17 M Decreased by -79.34% | -15.85 M Decreased by -110.29% | Decreased by -23.95% Decreased by -149.82% |
| Dec 31, 22 | 67.70 M Decreased by -73.10% | -24.08 M Decreased by -123.07% | Decreased by -35.56% Decreased by -185.77% |
| Sep 30, 22 | 105.66 M Decreased by -53.63% | 1.34 M Decreased by -98.90% | Increased by +1.27% Decreased by -97.64% |
| Jun 30, 22 | 125.34 M Decreased by -18.41% | 11.54 M Decreased by -85.54% | Increased by +9.20% Decreased by -82.28% |